Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs 3M Company — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.13 (market cap $3.94B), while 3M Company trades at $165 (market cap $83.94B). The key difference: 3M Company is far larger — about 21.3× Edgewise Therapeutics Inc. Common Stock's market cap, and 3M Company pays a 1.92% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and 3M Company for 169 Days on average.
| EWTX | MMM | |
|---|---|---|
Market Cap | $3.94B | $83.94B |
Volume | 810,104 | 2,547,210 |
Sector | Health | Industrials |
52-Week High | $48.35 | $183.79 |
52-Week Low | $14.89 | $141.10 |
Typical Hold Time | 0 Days | 169 Days |
Enterprise Value | $3.48B | $93.17B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
3M (MMM) trades at $162.77, up 1.17% today, showing resilience amid a bearish technical signal. The company delivered three consecutive quarterly EPS beats, with Q2 2026 actual EPS of $2.40 beating the $2.25 estimate. Revenue for 2025 was $24.95B with a net income margin of 11.9%, though down from 2024's 16.98%. Analyst consensus is split evenly between Buy and Hold ratings, with a $191.00 price target suggesting 17% upside. Recent news highlights operational improvements and litigation management progress.
The outlook for MMM is cautiously optimistic, supported by strong earnings performance and strategic initiatives, but weighed by high debt levels and mixed technical indicators. Investment opportunity lies in continued execution on margin expansion and growth in industrial segments, while risks include consumer segment weakness and macroeconomic pressures. The stock's current valuation at a P/E of 28.91 requires sustained earnings growth to justify further appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
